Cel-Sci Corp. (CVM)
XASE:CVM
CVM Stock Chart & Stats
$5.19
-$0.03(-7.92%)
At close: 4:00 PM EST
$5.19
-$0.03(-7.92%)
Day’s Range― - ―
52-Week Range$1.98 - $13.48
Previous Close$0.36
Volume1.47M
Average Volume (3M)125.69K
Market Cap
$34.42M
Enterprise Value$32.32M
Total Cash (Recent Filing)$6.28M
Total Debt (Recent Filing)$10.63M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding8,457,967
10 Day Avg. Volume66,836
30 Day Avg. Volume125,686
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.34
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-8.38
Enterprise Value/Ebitda-1.67
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4.16
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Contract Manufacturing CapabilityCEL-SCI’s GMP manufacturing and development services create a durable non-product revenue channel that can generate milestone and service fees. This asset base supports long-term cash generation, partnership opportunities, and diversification versus sole reliance on therapeutic approval.
Focused Clinical-stage AssetA single, well-defined lead candidate focused on a specific oncology indication provides a clear clinical and regulatory pathway. Success or credible trial progress could unlock commercialization, licensing, or partnership value, concentrating resources efficiently over the medium term.
Narrowing Net LossesThe multiyear reduction in net losses suggests improved expense control and operational discipline. Persistent but narrowing losses can extend runway between financings and demonstrate management’s ability to prioritize spending while advancing trials and manufacturing services.
Bears Say
Pre-revenue And Financing RelianceAs a pre-revenue biotech, CEL-SCI depends on external capital to fund R&D and operations. This structural reliance increases dilution and execution risk, tying sustainability to access to markets or partners rather than to internally generated product revenues.
Balance Sheet Volatility / Anomalous 2025 DebtThe extreme 2025 debt outlier and volatile leverage metrics indicate either material one-off financing or data reliability issues. Either scenario raises long-term financing and going-concern risk, undermining financial flexibility and making planning unpredictable.
Persistent Negative Operating Cash FlowConsistent negative operating and free cash flows mean the company must repeatedly raise capital or secure service contracts to fund operations. This erodes optionality for R&D investment and capacity expansion, constraining strategic choices absent new sustainable revenue.
Cel-Sci News
CVM FAQ
What was Cel-Sci Corp.’s price range in the past 12 months?
Cel-Sci Corp. lowest stock price was $1.98 and its highest was $13.48 in the past 12 months.
What is Cel-Sci Corp.’s market cap?
Cel-Sci Corp.’s market cap is $34.42M.
When is Cel-Sci Corp.’s upcoming earnings report date?
Cel-Sci Corp.’s upcoming earnings report date is May 14, 2026 which is in 31 days.
How were Cel-Sci Corp.’s earnings last quarter?
Cel-Sci Corp. released its earnings results on Feb 18, 2026. The company reported -$0.68 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.68.
Is Cel-Sci Corp. overvalued?
According to Wall Street analysts Cel-Sci Corp.’s price is currently Overvalued.
Does Cel-Sci Corp. pay dividends?
Cel-Sci Corp. does not currently pay dividends.
What is Cel-Sci Corp.’s EPS estimate?
Cel-Sci Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cel-Sci Corp. have?
Cel-Sci Corp. has 8,457,967 shares outstanding.
What happened to Cel-Sci Corp.’s price movement after its last earnings report?
Cel-Sci Corp. reported an EPS of -$0.68 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.368%.
Which hedge fund is a major shareholder of Cel-Sci Corp.?
Currently, no hedge funds are holding shares in CVM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cel-Sci Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-68.94%
12-Months-Change
Fundamentals
Return on Equity
-226.10%
Trailing 12-Months
Asset Growth
-10.91%
Trailing 12-Months
Company Description
Cel-Sci Corp.
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Technical Analysis
Ownership Overview
2.51% Insiders
3.60% Mutual Funds
0.09% Other Institutional Investors
91.04% Public Companies and
Individual Investors